Tearsheet

Alkermes (ALKS)

Market Price (4/12/2026): $33.48 | Market Cap: $5.5 Bil
Sector: Health Care | Industry: Pharmaceuticals

Alkermes (ALKS)

Market Price (4/12/2026): $33.48
Market Cap: $5.5 Bil
Sector: Health Care
Industry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Attractive cash flow generation
CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%

Attractive yield
FCF Yield is 8.7%

Low stock price volatility
Vol 12M is 40%

Megatrend and thematic drivers
Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

Weak multi-year price returns
2Y Excs Rtn is -3.3%, 3Y Excs Rtn is -43%

Meaningful short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%

Weak revenue growth
Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.2%, Rev Chg QQuarterly Revenue Change % is -11%

Key risks
ALKS key risks include [1] declining sales of its core products, Show more.

0	Attractive cash flow generation CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 35%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 33%
1	Attractive yield FCF Yield is 8.7%
2	Low stock price volatility Vol 12M is 40%
3	Megatrend and thematic drivers Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
4	Weak multi-year price returns 2Y Excs Rtn is -3.3%, 3Y Excs Rtn is -43%
5	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 11%
6	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -5.2%, Rev Chg QQuarterly Revenue Change % is -11%
7	Key risks ALKS key risks include [1] declining sales of its core products, Show more.

Valuation, Metrics & Events

	4/12/26	2025	2024	2023	2022
Share Price CYE	$33.48	$33.02	$27.07	$28.19	$26.31
Market Cap CYE ($ Bil)	5.5	5.4	4.5	4.7	4.3
Total Debt ($ Bil)	0.1	0.1	0.4	0.4	0.4
Total Cash ($ Bil)	0.6	0.9	0.7	0.6	0.5
Enterprise Value ($ Bil)	5.0	5.5	4.9	5.1	4.7
Valuation Ratios
P/S TTM	3.8	3.6	2.6	4.2	3.6
P/EBIT TTM	18.2	12.3	9.0	251.4	60.2
P/E TTM	22.9	15.3	10.5	-28.3	-69.3
P/FCF TTM	11.5	11.2	11.5	-78.5	30.6
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1	4.3	6.0
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7	-1.3	-2.2
P/E TTM (Sector)	-1.8	-1.3	-2.0	-1.5	-2.2
P/FCF TTM (Sector)	-1.7	-1.2	-2.0	-1.5	-2.5

	4/12/26	2025	2024
Share Price CYE	$33.48	$33.02	$27.07
Market Cap CYE ($ Bil)	5.5	5.4	4.5
Total Debt ($ Bil)	0.1	0.1	0.4
Total Cash ($ Bil)	0.6	0.9	0.7
Enterprise Value ($ Bil)	5.0	5.5	4.9
Valuation Ratios
P/S TTM	3.8	3.6	2.6
P/EBIT TTM	18.2	12.3	9.0
P/E TTM	22.9	15.3	10.5
P/FCF TTM	11.5	11.2	11.5
Sector Ratios
P/S TTM (Sector)	3.7	3.3	4.1
P/EBIT TTM (Sector)	-1.7	-1.3	-1.7
P/E TTM (Sector)	-1.8	-1.3	-2.0
P/FCF TTM (Sector)	-1.7	-1.2	-2.0

	ALKS	S&P 500
REVENUE GROWTH	POOR
Rev LTM ($ Bil)	1.5
Rev Chg Q	-10.6%	7.5%
Rev Chg LTM	-5.2%	6.8%
Rev Chg 3Y Avg	12.7%	5.7%
PROFITABILITY	GOOD
Op Inc LTM ($ Bil)	0.3
CFO LTM ($ Bil)	0.5
Net Inc LTM ($ Bil)	0.2
Op Mgn LTM	17.2%	18.6%
CFO/Rev LTM	35.3%	20.6%
Net Inc Mgn	16.4%	12.8%
VALUATION	MODERATE
P/S	3.8	3.2
P/CFO	10.6	15.4
P/FCF	11.5	19.8
P/E	22.9	24.1
STABILITY	VERY GOOD
Debt/Equity	0.01	0.21
Cash/Assets	0.24	0.07

AI Analysis | Feedback

Metric	Value	Date	Source
LYBALVI® Total Prescription Growth (Year-over-Year)	25%	9302025	Link
VIVITROL® Net Sales Attributable to Alcohol Dependence	approximately 75% of VIVITROL volume	5012025	Link
ARISTADA® Prescriber Breadth	Increased prescriber breadth and strong new-to-brand prescriptions	10282025	Link
Number of Clinical Trials for Alixorexton (ALKS 2680)	3 Phase 2 studies (Vibrance-1, Vibrance-2, Vibrance-3)	10232025	Link
Patient Enrollment in Alixorexton (ALKS 2680) Vibrance-1 Study	92	9082025	Link

Upcoming
5/07/2026	Earnings Release	Rev: $362 Mil (E) EPS: $-0.57 (E)

Price Chart

Return (1M):

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

Alkermes (ALKS) stock has gained about 20% since 12/31/2025 because of the following key factors:

1. Alixorexton received Breakthrough Therapy Designation for Narcolepsy Type 1.

On January 6, 2026, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to alixorexton, Alkermes' investigational oral orexin 2 receptor agonist, for the treatment of narcolepsy type 1 (NT1). This designation was based on positive Phase 1 and Phase 2 clinical data, including statistically significant improvements in wakefulness observed in the VIBRANCE-1 study, signaling a potentially accelerated development and review process for this key pipeline asset.

2. The company completed the strategic acquisition of Avadel Pharmaceuticals plc.

Alkermes completed its acquisition of Avadel Pharmaceuticals plc on February 12, 2026, significantly strengthening its position in the sleep medicine market. This acquisition brought LUMRYZ (sodium oxybate), an FDA-approved, once-nightly oxybate treatment for narcolepsy, into Alkermes' commercial portfolio. LUMRYZ is expected to generate substantial revenue, projected to surpass $350 million in annual sales in 2026 and exceed $450 million by 2028.

Show more

Stock Movement Drivers

Fundamental Drivers

The 19.7% change in ALKS stock from 12/31/2025 to 4/12/2026 was primarily driven by a 68.0% change in the company's P/E Multiple.

(LTM values as of)	12312025	4122026	Change
Stock Price ($)	27.98	33.48	19.7%
Change Contribution By:
Total Revenues ($ Mil)	1,521	1,476	-3.0%
Net Income Margin (%)	22.3%	16.4%	-26.5%
P/E Multiple	13.6	22.9	68.0%
Shares Outstanding (Mil)	165	165	-0.2%
Cumulative Contribution			19.7%

LTM = Last Twelve Months as of date shown

Market Drivers

12/31/2025 to 4/12/2026

	Return	Correlation
ALKS	19.2%
Market (SPY)	-5.4%	23.5%
Sector (XLV)	-4.8%	46.8%

Fundamental Drivers

The 11.6% change in ALKS stock from 9/30/2025 to 4/12/2026 was primarily driven by a 61.3% change in the company's P/E Multiple.

(LTM values as of)	9302025	4122026	Change
Stock Price ($)	30.00	33.48	11.6%
Change Contribution By:
Total Revenues ($ Mil)	1,505	1,476	-2.0%
Net Income Margin (%)	23.1%	16.4%	-29.3%
P/E Multiple	14.2	22.9	61.3%
Shares Outstanding (Mil)	165	165	-0.2%
Cumulative Contribution			11.6%

LTM = Last Twelve Months as of date shown

Market Drivers

9/30/2025 to 4/12/2026

	Return	Correlation
ALKS	11.2%
Market (SPY)	-2.9%	23.4%
Sector (XLV)	6.3%	36.5%

Fundamental Drivers

The 1.4% change in ALKS stock from 3/31/2025 to 4/12/2026 was primarily driven by a 57.3% change in the company's P/E Multiple.

(LTM values as of)	3312025	4122026	Change
Stock Price ($)	33.02	33.48	1.4%
Change Contribution By:
Total Revenues ($ Mil)	1,558	1,476	-5.2%
Net Income Margin (%)	23.6%	16.4%	-30.5%
P/E Multiple	14.6	22.9	57.3%
Shares Outstanding (Mil)	162	165	-2.1%
Cumulative Contribution			1.4%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2025 to 4/12/2026

	Return	Correlation
ALKS	1.0%
Market (SPY)	16.3%	33.7%
Sector (XLV)	2.3%	43.5%

Fundamental Drivers

The 27.8% change in ALKS stock from 3/31/2023 to 4/12/2026 was primarily driven by a 32.7% change in the company's Total Revenues ($ Mil).

(LTM values as of)	3312023	4122026	Change
Stock Price ($)	26.21	33.48	27.8%
Change Contribution By:
Total Revenues ($ Mil)	1,112	1,476	32.7%
P/S Multiple	3.9	3.8	-3.2%
Shares Outstanding (Mil)	164	165	-0.6%
Cumulative Contribution			27.8%

LTM = Last Twelve Months as of date shown

Market Drivers

3/31/2023 to 4/12/2026

	Return	Correlation
ALKS	27.3%
Market (SPY)	63.3%	24.3%
Sector (XLV)	19.1%	36.0%

Return vs. Risk

Price Returns Compared

	2021	2022	2023	2024	2025	2026	Total [1]
Returns
ALKS Return	17%	12%	14%	4%	-3%	25%	88%
Peers Return	5%	110%	-4%	-30%	42%	-10%	92%
S&P 500 Return	27%	-19%	24%	23%	16%	-0%	82%
Monthly Win Rates [3]
ALKS Win Rate	58%	58%	58%	42%	50%	50%
Peers Win Rate	55%	57%	50%	38%	63%	25%
S&P 500 Win Rate	75%	42%	67%	75%	67%	50%
Max Drawdowns [4]
ALKS Max Drawdown	-9%	-6%	-10%	-17%	-9%	-3%
Peers Max Drawdown	-31%	-27%	-33%	-43%	-35%	-18%
S&P 500 Max Drawdown	-1%	-25%	-1%	-2%	-15%	-7%

[1] Cumulative total returns since the beginning of 2021
[2] Peers: NBIX, ACAD, BTAI, INDV, JNJ. See ALKS Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 4/10/2026 (YTD)

How Low Can It Go

Unique Key	Event	ALKS	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-33.2%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	49.7%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	562 days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-38.5%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	62.6%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	268 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-74.3%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	289.0%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	Not Fully Recovered days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-67.1%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	204.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	952 days	1,480 days

Compare to NBIX, ACAD, BTAI, INDV, JNJ

In The Past

Alkermes's stock fell -33.2% during the 2022 Inflation Shock from a high on 9/28/2021. A -33.2% loss requires a 49.7% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Alkermes (ALKS)

Business Description Analogies Products Customers Suppliers Management Key Risks Emerging Threats Market Size Revenue Drivers Capital Allocation

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

AI Analysis | Feedback

Here are a few analogies for Alkermes (ALKS):

Biogen for psychiatric and addiction therapies. (Like Biogen's focus on neuroscience, Alkermes specializes in mental health and addiction treatments.)
Vertex Pharmaceuticals for mental health and addiction. (Similar to Vertex's specialization in challenging diseases like cystic fibrosis, Alkermes focuses on complex psychiatric and addiction conditions.)

AI Analysis | Feedback

ARISTADA: An intramuscular injectable suspension used for the treatment of schizophrenia.
VIVITROL: Used for the treatment of alcohol dependence and the prevention of opioid dependence.
RISPERDAL CONSTA: Treats schizophrenia and bipolar I disorder.
INVEGA SUSTENNA: Addresses schizophrenia and schizoaffective disorder.
XEPLION: Treats schizophrenia and schizoaffective disorder.
INVEGA TRINZA: Treats schizophrenia and schizoaffective disorder.
TREVICTA: Treats schizophrenia and schizoaffective disorder.
VUMERITY: For the treatment of relapsing forms of multiple sclerosis in adults.
LYBALVI: An oral atypical antipsychotic drug candidate in development for schizophrenia and bipolar I disorder.
nemvaleukin alfa: An engineered fusion protein in development to expand tumor-killing immune cells.

AI Analysis | Feedback

Alkermes (ALKS) sells its pharmaceutical products primarily to other companies.

Based on the provided company description, a major customer and partner company is:

Janssen Pharmaceutica (a subsidiary of Johnson & Johnson, NYSE: JNJ). Alkermes has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International for several products, including RISPERDAL CONSTA, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA.

For its other commercialized products (such as ARISTADA, VIVITROL, and VUMERITY), Alkermes typically sells to pharmaceutical wholesalers and distributors, which then supply pharmacies, hospitals, and healthcare providers. However, specific names of these wholesale customer companies are not provided in the company description.

AI Analysis | Feedback

null

AI Analysis | Feedback

Richard Pops, Chairman and Chief Executive Officer

Richard Pops joined Alkermes as Chief Executive Officer in 1991 and currently serves as Chairman and CEO. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly-traded biopharmaceutical company with over 2,000 employees. He has also served on the boards of directors of other publicly-traded biotechnology companies, including Neurocrine Biosciences, and previously Acceleron Pharma and Epizyme. Mr. Pops is scheduled to retire from his CEO role on July 31, 2026, and will continue to serve as Chairman of the Board and an advisor to the executive team.

Joshua Reed, Chief Financial Officer

Joshua Reed was appointed Chief Financial Officer of Alkermes, effective September 15, 2025. He brings over 30 years of financial leadership experience, with a strong focus on the biotechnology and pharmaceutical sectors. Prior to joining Alkermes, Mr. Reed served as CFO of Omega Therapeutics and Aldeyra Therapeutics. He also spent more than a decade at Bristol Myers Squibb, where he held the position of Vice President and Head of Finance Operations for the U.S. and Puerto Rico, and held roles at JPMorganChase, Credit Suisse First Boston, and Chase Manhattan Bank. Mr. Reed currently serves on the board of directors of Scholar Rock Holding Corporation.

Blair Jackson, Executive Vice President, Chief Operating Officer

Blair Jackson serves as Alkermes' Executive Vice President, Chief Operating Officer, a position he has held since January 2021. He joined Alkermes in 1999 and has held various scientific and corporate roles within the company. Mr. Jackson is responsible for Alkermes' strategic planning and corporate services, including global operations, quality, information technology, business development, and corporate planning. He is slated to succeed Richard Pops as Chief Executive Officer, effective August 1, 2026. Additionally, he served as interim principal financial officer from February 2024 to September 2025.

C. Todd Nichols, Senior Vice President, Chief Commercial Officer

C. Todd Nichols is the Senior Vice President, Chief Commercial Officer at Alkermes, a role he assumed in May 2020 after joining the company in May 2019 as SVP, Sales & Marketing. He leads the Sales, Marketing, Market Access, and Commercial Operations functions, overseeing the commercial strategy for Alkermes' marketed medicines. Mr. Nichols brings over 20 years of extensive commercial experience in the biopharmaceutical sector, having previously served as Vice President of Marketing and Sales, Inflammation and Immunology at Celgene. His career also includes marketing and sales leadership positions at Biogen, Merck, and Schering-Plough.

Craig Hopkinson, M.D., Executive Vice President, Research & Development and Chief Medical Officer

Dr. Craig Hopkinson serves as Alkermes' Executive Vice President, Research & Development and Chief Medical Officer.

AI Analysis | Feedback

Intense Competition and Pricing Pressure: Alkermes operates in the highly competitive Central Nervous System (CNS) therapeutic area, where its proprietary long-acting injectables like ARISTADA, VIVITROL, and LYBALVI face significant rivalry for market share from both branded and generic drug manufacturers. This competitive landscape, coupled with pressure from national payers demanding proof of value for high-cost treatments, can lead to intense pricing battles and erosion of profitability. The acquisition of LUMRYZ for narcolepsy also introduces the company to an area with emerging competition from other OX2R agonists.
Regulatory and Clinical Development Challenges: As a biopharmaceutical company, Alkermes is subject to stringent and evolving regulatory approval processes by agencies such as the FDA and their international counterparts. Delays, failures, or adverse decisions in securing regulatory approvals for new or existing products can significantly impact business operations, financial health, and investor confidence. Furthermore, the success of Alkermes' future growth is highly dependent on its research and development pipeline, including candidates like ALKS 2680. Clinical trial failures or setbacks can lead to increased costs and delays, as exemplified by past program cancellations.
Dependence on Key Products and Patent Expirations: A substantial portion of Alkermes' revenue is currently reliant on a few key proprietary products, including ARISTADA, VIVITROL, and LYBALVI. While the company has been shifting towards proprietary product sales, the eventual loss of market exclusivity for these or other products, or increased competition, could lead to significant declines in sales. Even recently acquired products, like LUMRYZ, are projected to face sales declines post-2030 due to patent expirations and increased competition.

AI Analysis | Feedback

The increasing market preference and competitive emergence of highly effective oral therapies or less burdensome administration methods for chronic psychiatric conditions, which could diminish the market share of Alkermes' substantial portfolio of long-acting injectable (LAI) products for schizophrenia and bipolar I disorder. Alkermes' own development of LYBALVI, an oral atypical antipsychotic for these same indications, suggests an internal recognition of this potential market shift.

AI Analysis | Feedback

Alkermes plc (ALKS) develops and commercializes pharmaceutical products across various therapeutic areas. The addressable markets for their main products or services are detailed below:

ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia:
The U.S. market for antipsychotics was estimated at $3 billion in 2022, with long-acting injectables (LAIs) representing approximately 20% or $600 million. ARISTADA competes within this broader market.
VIVITROL (naltrexone) for the treatment of alcohol dependence and prevention of opioid dependence:
Alkermes reported net sales of $467 million for VIVITROL in fiscal year 2023. Projections for 2024 are between $470 million and $490 million, and for 2025, between $490 million and $510 million. The Alcohol Use Disorder Market in the seven major markets (7MM: United States, EU4, UK, and Japan) was valued at approximately $1,106 million in 2025 and is projected to reach $3,489 million by 2034. The U.S. market size was approximately $1,106 million in 2025. The global naltrexone and buprenorphine market size was estimated at $4.17 billion in 2024 and is projected to reach $9.80 billion by 2033, growing at a CAGR of 9.25%. North America held the largest share of 39.4% in 2024.
RISPERDAL CONSTA (risperidone) for the treatment of schizophrenia and bipolar I disorder:
The global market size for RISPERDAL CONSTA was estimated at $3.2 billion in 2022, with a projected Compound Annual Growth Rate (CAGR) of approximately 4.5% from 2023-2028. North America accounts for about 50% of these sales. The broader global antipsychotic drugs market size was valued at $18.51 billion in 2025 and is projected to grow to $27.48 billion by 2034, with North America dominating with a 52.32% share in 2025.
INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, and TREVICTA (paliperidone palmitate long-acting injectables) for the treatment of schizophrenia and schizoaffective disorder:
The global schizophrenia treatment market was approximately $4.6 billion in 2022, with injectable antipsychotics accounting for roughly 20% of sales. INVEGA SUSTENNA and its related formulations collectively had global sales exceeding $3 billion in 2022. The U.S. market size for antipsychotics was estimated at $3 billion in 2022, with long-acting injectables (LAIs) representing roughly 20% ($600 million). The total Schizophrenia Market Size in the 7MM was approximately $7,972.0 million in 2022, and in the US, it was approximately $5,749.0 million in 2022. The global schizophrenia market size was valued at approximately $8,000 million in 2024, with the U.S. market at nearly $6 billion in 2024.
VUMERITY (diroximel fumarate) for the treatment of relapsing forms of multiple sclerosis in adults:
The global multiple sclerosis drugs market size was valued at $21.07 billion in 2025 and is projected to grow to $53.20 billion by 2034, at a CAGR of 11.08%. North America dominated this market with a 48.51% share in 2025. The global multiple sclerosis therapeutics market size reached $27.42 billion in 2024 and is expected to reach $46.22 billion by 2033, growing at a CAGR of 6.1%. North America holds the largest revenue share of 43.17% in 2024. The Multiple Sclerosis Treatment Market in the 7MM was valued at approximately $20 billion in 2024, and the U.S. market size was approximately $16 billion in 2024.
LYBALVI (olanzapine and samidorphan) for the treatment of adults with schizophrenia and bipolar I disorder:
LYBALVI was approved in June 2021 and commercially available in the U.S. since October 2021. The global antipsychotic drugs market size was valued at $18.51 billion in 2025 and is projected to grow to $27.48 billion by 2034. North America dominated with a 52.32% share in 2025. The global antipsychotic drugs market was valued at $18.04 billion in 2023 and is expected to reach around $37.40 billion by 2032. The total Schizophrenia Market Size in the 7MM was approximately $7,972.0 million in 2022, and in the U.S. was approximately $5,749.0 million in 2022. The global schizophrenia market size was valued at approximately $8,000 million in 2024, with the U.S. market at nearly $6 billion in 2024.
nemvaleukin alfa, an engineered fusion protein for solid tumors:
Nemvaleukin alfa is being developed for solid tumors, including mucosal melanoma. The global cancer immunotherapy market was valued at $125.7 billion in 2023 and is estimated to grow at a 9.3% CAGR from 2024 to 2032, reaching $277.4 billion.

AI Analysis | Feedback

Alkermes (ALKS) is expected to drive future revenue growth over the next 2-3 years through several key initiatives and product advancements:

Continued Growth of Key Proprietary Neuroscience Products: Alkermes anticipates sustained revenue growth from its established proprietary products, including ARISTADA for schizophrenia, VIVITROL for alcohol and opioid dependence, and LYBALVI for schizophrenia and bipolar I disorder. In 2025, the proprietary product portfolio grew 9% year over year, with LYBALVI showing particularly strong growth. The company's 2026 guidance projects proprietary product net sales of $1.52 billion to $1.6 billion, demonstrating continued confidence in these core assets.
Integration and Expansion of LUMRYZ Following the Avadel Acquisition: The recent acquisition of Avadel Pharmaceuticals, completed in February 2026, is a significant strategic move that introduces LUMRYZ into Alkermes' commercial portfolio. This acquisition accelerates Alkermes' entry into the commercial sleep medicine market and is expected to be a substantial new revenue stream. LUMRYZ generated $279 million in net sales in 2025 and is projected to contribute $350 million to $370 million in 2026, with further growth anticipated in the narcolepsy and idiopathic hypersomnia markets.
Advancement and Potential Launch of Alixorexton (ALKS 2680): Alixorexton, an investigational orexin-2 receptor agonist for narcolepsy and idiopathic hypersomnia, is considered a transformative opportunity for Alkermes. The company plans to enter Phase 3 studies following a rigorous Phase 2 program and recently granted FDA breakthrough therapy designation. This asset is expected to significantly enhance long-term growth and market entry into new areas within central nervous system disorders.
Expansion of the Orexin Portfolio: Beyond alixorexton, Alkermes is progressing other orexin 2 receptor agonists in its pipeline, including ALKS 7290 for ADHD and ALKS 4510 for fatigue in neurodegenerative disorders. Both are advancing toward Phase 2 trials in 2026, indicating a broader strategic focus on the orexin system to drive future revenue streams.

AI Analysis | Feedback

Share Repurchases

Alkermes announced a share repurchase program in February 2024, authorizing the repurchase of up to $400 million of its shares.
In 2024, the company repurchased approximately 7.9 million ordinary shares for a total of $200 million under this program.
As of September 30, 2024, $200 million remained authorized for future share repurchases, with no shares repurchased in 2025.

Outbound Investments

In February 2026, Alkermes completed the acquisition of Ireland-based Avadel Pharmaceuticals for a total transaction value of approximately $2.1 billion. This acquisition was financed using approximately $775 million of cash from the balance sheet and $1.525 billion in term loans due in 2031. The acquisition adds Lumryz to Alkermes' commercial portfolio, accelerating its entry into the sleep medicine market.
The company completed the separation of its former oncology business into an independent, publicly-traded company, Mural Oncology plc, in November 2023.

Capital Expenditures

Alkermes expects to spend $40 million to $50 million on capital expenditures in 2026. These expenditures are anticipated to support strategic initiatives, including advancing its pipeline programs.

Interactive Breakdown

null

null

Better Bets vs. Alkermes (ALKS)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

PTCT (44.9% | 3.3x)

PTC Therapeutics

ACAD (28.1% | 3.4x)

ACADIA Pharmaceuticals

PAHC (15.3% | 1.6x)

Phibro Animal Health

BCRX (50.8% | 2.3x)

BioCryst Pharmaceuticals

ANIP (41.3% | 1.8x)

ANI Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

PTCT (44.9% | 6.6x)

PTC Therapeutics

PAHC (15.3% | 13.9x)

Phibro Animal Health

BCRX (50.8% | 5.9x)

BioCryst Pharmaceuticals

ANIP (41.3% | 20.0x)

ANI Pharmaceuticals

COLL (19.1% | 6.3x)

Collegium Pharmaceutical

Higher Rev Chg LTM (Value for ALKS: -5.2%)

LLY (44.7%)

Eli Lilly

JNJ (6.0%)

Johnson & Johnson

MRK (1.3%)

Merck

BMY (-0.2%)

Bristol-Myers Squibb

PFE (-1.6%)

Pfizer

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

APLS (183.8%)

Apellis Pharmaceuticals

PTCT (44.9%)

PTC Therapeutics

LLY (32.1%)

Eli Lilly

ACAD (28.1%)

ACADIA Pharmaceuticals

CORT (24.3%)

Corcept Therapeutics

Higher Op Mgn LTM (Value for ALKS: 17.2%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

BMY (28.5%)

Bristol-Myers Squibb

PFE (27.8%)

Pfizer

JNJ (27.2%)

Johnson & Johnson

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

INVA (47.9%)

Innoviva

IRWD (42.9%)

Ironwood Pharmaceuticals

COLL (42.2%)

Collegium Pharmaceutical

PTCT (41.1%)

PTC Therapeutics

BCRX (39.7%)

BioCryst Pharmaceuticals

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

INVA (47.9%)

Innoviva

SIGA (45.6%)

SIGA Technologies

IRWD (42.9%)

Ironwood Pharmaceuticals

COLL (42.0%)

Collegium Pharmaceutical

BCRX (39.4%)

BioCryst Pharmaceuticals

Higher Total Yield (Value for ALKS: 4.4%)

PFE (11.5%)

Pfizer

BMY (10.1%)

Bristol-Myers Squibb

MRK (8.8%)

Merck

ZTS (6.9%)

Zoetis

JNJ (6.8%)

Johnson & Johnson

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

MCK (13.3% | 0.3x)

McKesson

CI (15.3% | 0.3x)

Cigna

INCY (15.0% | 3.7x)

Incyte

ENSG (18.7% | 2.3x)

Ensign

BMRN (15.4% | 3.3x)

BioMarin Pharmaceutical

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

MCK (13.3% | 18.2x)

McKesson

RMD (12.9% | 18.1x)

ResMed

UTHR (18.1% | 16.4x)

United Therapeutics

INCY (15.0% | 14.1x)

Incyte

NBIX (24.3% | 20.3x)

Neurocrine Biosciences

Higher Rev Chg LTM (Value for ALKS: -5.2%)

LLY (44.7%)

Eli Lilly

UNH (11.8%)

UnitedHealth

ABBV (8.6%)

AbbVie

JNJ (6.0%)

Johnson & Johnson

MRK (1.3%)

Merck

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

LLY (32.1%)

Eli Lilly

ISRG (17.4%)

Intuitive Surgical

BSX (16.6%)

Boston Scientific

CI (15.3%)

Cigna

MCK (13.3%)

McKesson

Higher Op Mgn LTM (Value for ALKS: 17.2%)

LLY (45.6%)

Eli Lilly

MRK (34.0%)

Merck

ABBV (32.8%)

AbbVie

JNJ (27.2%)

Johnson & Johnson

AMGN (24.7%)

Amgen

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

RPRX (104.7%)

Royalty Pharma

UTHR (49.1%)

United Therapeutics

VEEV (44.3%)

Veeva Systems

EXEL (38.1%)

Exelixis

RMD (35.5%)

ResMed

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

RPRX (104.7%)

Royalty Pharma

KRYS (48.5%)

Krystal Biotech

VEEV (44.3%)

Veeva Systems

EXEL (36.4%)

Exelixis

RMD (32.9%)

ResMed

Higher Total Yield (Value for ALKS: 4.4%)

MRK (8.8%)

Merck

UNH (7.2%)

UnitedHealth

JNJ (6.8%)

Johnson & Johnson

AMGN (6.8%)

Amgen

ABT (6.1%)

Abbott Laboratories

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

BRK-B (27.0% | 2.5x)

Berkshire Hathaway

UBER (17.7% | 2.8x)

Uber Technologies

COF (16.8% | 2.3x)

Capital One Financial

PGR (21.0% | 1.3x)

Progressive

MELI (38.9% | 3.1x)

MercadoLibre

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

MSFT (14.4% | 19.3x)

Microsoft

META (19.9% | 19.1x)

Meta Platforms

MU (45.3% | 16.8x)

Micron Technology

BKNG (16.5% | 15.0x)

Booking

NEM (26.2% | 12.0x)

Newmont

Higher Rev Chg LTM (Value for ALKS: -5.2%)

NVDA (65.5%)

NVIDIA

MSFT (16.7%)

Microsoft

GOOGL (15.1%)

Alphabet

AMZN (12.4%)

Amazon.com

AAPL (10.1%)

Apple

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

NVDA (101.8%)

NVIDIA

BRK-B (27.0%)

Berkshire Hathaway

AVGO (26.2%)

Broadcom

META (19.9%)

Meta Platforms

MSFT (14.4%)

Microsoft

Higher Op Mgn LTM (Value for ALKS: 17.2%)

NVDA (60.4%)

NVIDIA

MSFT (46.7%)

Microsoft

AVGO (41.5%)

Broadcom

AAPL (32.4%)

Apple

GOOGL (32.0%)

Alphabet

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

META (57.6%)

Meta Platforms

MSFT (52.5%)

Microsoft

NVDA (47.6%)

NVIDIA

AVGO (43.5%)

Broadcom

GOOGL (40.9%)

Alphabet

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

V (55.4%)

Visa

MA (50.1%)

Mastercard

PLTR (46.9%)

Palantir Technologies

NVDA (44.8%)

NVIDIA

AVGO (42.3%)

Broadcom

Higher Total Yield (Value for ALKS: 4.4%)

XOM (7.1%)

Exxon Mobil

JPM (6.7%)

JPMorgan Chase

BRK-B (6.5%)

Berkshire Hathaway

MSFT (5.2%)

Microsoft

MU (5.2%)

Micron Technology

Best Bets in Health Care

What You Pay

P/EBIT (Value for ALKS: 18.2x)

RPRX (12.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.0x)

Veeva Systems

HALO (16.5x)

Halozyme Therapeutics

UTHR (14.3x)

United Therapeutics

CPRX (11.9x)

Catalyst Pharmaceuticals

BMY (10.6x)

Bristol-Myers Squibb

RMD (18.1x)

ResMed

AMGN (16.1x)

Amgen

PBH (8.8x)

Prestige Consumer Healthcare

P/E (Value for ALKS: 22.8x)

RPRX (26.6x)

Royalty Pharma

DOCS (16.5x)

Doximity

VEEV (27.3x)

Veeva Systems

HALO (25.2x)

Halozyme Therapeutics

UTHR (18.6x)

United Therapeutics

CPRX (14.3x)

Catalyst Pharmaceuticals

BMY (16.9x)

Bristol-Myers Squibb

RMD (22.5x)

ResMed

AMGN (24.5x)

Amgen

PBH (14.5x)

Prestige Consumer Healthcare

What You Get

Rev Chg 3Y Avg (Value for ALKS: 12.7%)

RPRX (2.1%)

Royalty Pharma

DOCS (16.7%)

Doximity

VEEV (14.1%)

Veeva Systems

HALO (28.5%)

Halozyme Therapeutics

UTHR (18.1%)

United Therapeutics

CPRX (43.1%)

Catalyst Pharmaceuticals

BMY (1.5%)

Bristol-Myers Squibb

RMD (12.9%)

ResMed

AMGN (11.9%)

Amgen

PBH (-0.1%)

Prestige Consumer Healthcare

Rev Chg LTM (Value for ALKS: -5.2%)

RPRX (5.1%)

Royalty Pharma

DOCS (15.9%)

Doximity

VEEV (16.3%)

Veeva Systems

HALO (37.6%)

Halozyme Therapeutics

UTHR (10.6%)

United Therapeutics

CPRX (19.8%)

Catalyst Pharmaceuticals

BMY (-0.2%)

Bristol-Myers Squibb

RMD (9.6%)

ResMed

AMGN (10.0%)

Amgen

PBH (-1.3%)

Prestige Consumer Healthcare

Rev Chg Q (Value for ALKS: -10.6%)

RPRX (4.8%)

Royalty Pharma

DOCS (9.8%)

Doximity

VEEV (16.0%)

Veeva Systems

HALO (51.6%)

Halozyme Therapeutics

UTHR (7.4%)

United Therapeutics

CPRX (7.6%)

Catalyst Pharmaceuticals

BMY (1.3%)

Bristol-Myers Squibb

RMD (11.0%)

ResMed

AMGN (8.6%)

Amgen

PBH (-2.4%)

Prestige Consumer Healthcare

FCF/Rev 3Y Avg (Value for ALKS: 26.6%)

RPRX (118.0%)

Royalty Pharma

DOCS (41.6%)

Doximity

VEEV (40.8%)

Veeva Systems

HALO (38.8%)

Halozyme Therapeutics

UTHR (34.1%)

United Therapeutics

CPRX (33.2%)

Catalyst Pharmaceuticals

BMY (27.9%)

Bristol-Myers Squibb

RMD (27.3%)

ResMed

AMGN (26.4%)

Amgen

PBH (22.3%)

Prestige Consumer Healthcare

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Date
0	DASHBOARDS
1	How Low Can Alkermes Stock Really Go?	10/17/2025
2	ALKS Dip Buy Analysis	07/10/2025
3	Alkermes Total Shareholder Return (TSR): 3.7% in 2024 and 10.0% 3-yr compounded annual returns (above peer average)	03/07/2025
4	Alkermes (ALKS) Operating Cash Flow Comparison	02/17/2025
5	Alkermes (ALKS) Net Income Comparison	02/15/2025
6	Alkermes (ALKS) Operating Income Comparison	02/14/2025
7	Alkermes (ALKS) Revenue Comparison	02/13/2025
8	Alkermes vs. Elanco Animal Health: With Return Forecast Of 17%, Elanco Animal Health Is A Better Bet	10/04/2024
9	Alkermes vs. S&P500 Correlation	10/03/2024
10	Alkermes Price Volatility	09/24/2024
11	ARTICLES
12	What’s Next For Alkermes Stock After A 16% Rise Last Month?	09/01/2021
13	With Vaccine Uncertainty Behind Us, Is It Time To Buy Underperforming Healthcare Stocks?	11/23/2020
14	ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?	10/19/2020
15	ACADIA, NovoCure & Alexion: How Are Out Of Favor Health Care Stocks Performing?	09/01/2020
16	Why Is Alkermes Stock Down 30% So Far This Year?	11/22/2019

	Title
0	DASHBOARDS
1	How Low Can Alkermes Stock Really Go?
2	ALKS Dip Buy Analysis
3	Alkermes Total Shareholder Return (TSR): 3.7% in 2024 and 10.0% 3-yr compounded annual returns (above peer average)
4	Alkermes (ALKS) Operating Cash Flow Comparison
5	Alkermes (ALKS) Net Income Comparison
6	Alkermes (ALKS) Operating Income Comparison
7	Alkermes (ALKS) Revenue Comparison
8	Alkermes vs. Elanco Animal Health: With Return Forecast Of 17%, Elanco Animal Health Is A Better Bet
9	Alkermes vs. S&P500 Correlation
10	Alkermes Price Volatility
11	ARTICLES
12	What’s Next For Alkermes Stock After A 16% Rise Last Month?
13	With Vaccine Uncertainty Behind Us, Is It Time To Buy Underperforming Healthcare Stocks?
14	ACADIA, Neurocrine, Alkermes Are Out Of Favor. Is It Time To Buy?
15	ACADIA, NovoCure & Alexion: How Are Out Of Favor Health Care Stocks Performing?
16	Why Is Alkermes Stock Down 30% So Far This Year?

Trade Ideas

Select ideas related to ALKS.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
PGNY_3312026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03312026	PGNY	Progyny	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	0.0%	0.0%	0.0%
CNC_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	CNC	Centene	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	2.3%	2.3%	-0.6%
OSCR_3272026_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	03272026	OSCR	Oscar Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.0%	3.0%	-2.6%
WAT_3202026_Monopoly_xInd_xCD_Getting_Cheaper	03202026	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	-0.4%	-0.4%	-3.3%
GILD_3202026_Quality_Momentum_RoomToRun_10%	03202026	GILD	Gilead Sciences	Quality	Q \| Momentum \| UpsideQuality Stocks with Momentum and Upside Buying quality stocks with strong momentum but still having room to run	1.6%	1.6%	-2.2%

Recent Active Movers

Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
OGN	Organon	2.3	27.8%	23.5%
LWLG	Lightwave Logic	1.4	25.6%	227.2%
POET	POET Technologies	0.6	15.8%	11.2%
ALAB	Astera Labs	25.3	15.1%	-10.4%
MANE	Veradermics	1.4	14.7%	82.3%
TTMI	TTM Technologies	12.6	13.0%	76.1%
AAOI	Applied Optoelectronics	10.6	13.0%	332.0%
FBYD	Falcons Beyond Global	0.5	12.6%	-18.9%
TE	T1 Energy	0.8	12.2%	-29.8%
CRWV	CoreWeave	51.7	10.9%	42.4%

Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
FSLY	Fastly	3.5	-21.7%	126.6%
REPL	Replimune	0.4	-19.5%	-51.0%
AKAM	Akamai Technologies	13.2	-16.7%	4.7%
FICO	Fair Isaac	21.9	-14.0%	-45.4%
SEZL	Sezzle	2.0	-13.6%	-5.9%
NET	Cloudflare	58.6	-13.5%	-15.3%
DOCN	DigitalOcean	6.9	-13.3%	57.1%
SMPL	Simply Good Foods	1.0	-11.5%	-48.0%
EVMN	Evommune	0.8	-11.0%	49.0%
GH	Guardant Health	10.1	-9.8%	-23.0%

Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
AEHR	Aehr Test Systems	2.1	58.9%	248.8%
CAR	Avis Budget	10.6	57.5%	133.7%
AAOI	Applied Optoelectronics	10.6	44.9%	332.0%
OGN	Organon	2.3	38.8%	23.5%
LWLG	Lightwave Logic	1.4	38.4%	227.2%
HUT	Hut 8	7.2	37.4%	43.9%
SLNO	Soleno Therapeutics	2.8	33.3%	13.7%
STAA	Staar Surgical	1.3	30.8%	14.5%
RIOT	Riot Platforms	5.8	29.1%	31.0%
CIFR	Cipher Digital	6.6	28.9%	12.0%

Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
REPL	Replimune	0.4	-43.4%	-51.0%
FSLY	Fastly	3.5	-31.1%	126.6%
SMPL	Simply Good Foods	1.0	-26.3%	-48.0%
AKAM	Akamai Technologies	13.2	-22.6%	4.7%
GWRE	Guidewire Software	10.0	-21.8%	-41.3%
OKTA	Okta	11.2	-21.5%	-27.2%
HUBS	HubSpot	10.1	-21.4%	-52.1%
NET	Cloudflare	58.6	-21.1%	-15.3%
VRDN	Viridian Therapeutics	1.4	-20.6%	-52.0%
SNOW	Snowflake	41.5	-20.2%	-44.8%

Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
XLO	Xilio Therapeutics	0.6	1475.9%	-5.1%
CAR	Avis Budget	10.6	196.4%	133.7%
SATL	Satellogic	1.0	135.7%	292.0%
LWLG	Lightwave Logic	1.4	111.2%	227.2%
APLS	Apellis Pharmaceuticals	5.2	110.5%	62.4%
FBYD	Falcons Beyond Global	0.5	92.1%	-18.9%
FLY	Firefly Aerospace	6.0	82.2%	67.8%
KOD	Kodiak Sciences	2.3	75.7%	54.2%
KODK	Eastman Kodak	1.2	74.0%	42.9%
ORKA	Oruka Therapeutics	3.2	73.1%	96.6%

Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
WVE	WAVE Life Sciences	1.3	-49.0%	-57.8%
VRDN	Viridian Therapeutics	1.4	-47.8%	-52.0%
MAZE	Maze Therapeutics	1.2	-47.1%	-35.6%
BUR	Burford Capital	1.0	-47.0%	-51.1%
FRMI	Fermi	2.9	-43.9%	-39.1%
TE	T1 Energy	0.8	-42.4%	-29.8%
REPL	Replimune	0.4	-39.7%	-51.0%
ADMA	ADMA Biologics	2.3	-38.1%	-46.8%
FIG	Figma	9.3	-34.8%	-51.4%
BOBS	Bobs Discount Furniture	1.4	-34.7%	-34.8%

Peer Comparisons

Peers to compare with:

Financials

	ALKS	NBIX	ACAD	BTAI	INDV	JNJ	Median
Name	Alkermes	Neurocri.	ACADIA P.	BioXcel .	Indivior.	Johnson .
Mkt Price	33.48	128.96	21.73	1.07	30.66	238.76	32.07
Mkt Cap	5.5	12.9	3.7	0.0	3.8	574.9	4.7
Rev LTM	1,476	2,860	1,072	1	1,240	94,193	1,358
Op Inc LTM	254	636	105	-50	266	25,596	260
FCF LTM	480	746	10	-58	-94	19,313	245
FCF 3Y Avg	413	555	61	-95	-147	18,383	237
CFO LTM	521	783	110	-58	-27	24,530	315
CFO 3Y Avg	454	589	95	-95	-97	23,862	274

Growth & Margins

	ALKS	NBIX	ACAD	BTAI	INDV	JNJ	Median
Name	Alkermes	Neurocri.	ACADIA P.	BioXcel .	Indivior.	Johnson .
Rev Chg LTM	-5.2%	21.4%	11.9%	-71.7%	4.3%	6.0%	5.2%
Rev Chg 3Y Avg	12.7%	24.3%	28.1%	86.8%	11.4%	2.6%	18.5%
Rev Chg Q	-10.6%	28.3%	9.4%	-30.1%	19.7%	9.1%	9.2%
QoQ Delta Rev Chg LTM	-3.0%	6.6%	2.3%	-14.6%	5.0%	2.2%	2.3%
Op Mgn LTM	17.2%	22.3%	9.8%	-7,829.8%	21.5%	27.2%	19.3%
Op Mgn 3Y Avg	23.0%	22.6%	2.8%	-7,612.0%	21.5%	25.6%	22.1%
QoQ Delta Op Mgn LTM	-6.4%	1.6%	0.8%	-1,121.5%	2.1%	1.5%	1.1%
CFO/Rev LTM	35.3%	27.4%	10.3%	-8,974.3%	-2.2%	26.0%	18.1%
CFO/Rev 3Y Avg	29.2%	24.4%	9.7%	-7,795.1%	-8.9%	26.7%	17.1%
FCF/Rev LTM	32.5%	26.1%	1.0%	-8,974.3%	-7.6%	20.5%	10.7%
FCF/Rev 3Y Avg	26.6%	23.0%	6.6%	-7,795.1%	-13.2%	20.6%	13.6%

Valuation

	ALKS	NBIX	ACAD	BTAI	INDV	JNJ	Median
Name	Alkermes	Neurocri.	ACADIA P.	BioXcel .	Indivior.	Johnson .
Mkt Cap	5.5	12.9	3.7	0.0	3.8	574.9	4.7
P/S	3.8	4.5	3.4	36.4	3.1	6.1	4.1
P/EBIT	18.2	20.3	35.2	-0.4	13.5	17.1	17.7
P/E	22.9	27.0	9.4	-0.3	18.3	21.4	19.9
P/CFO	10.6	16.5	33.6	-0.4	-141.9	23.4	13.6
Total Yield	4.4%	3.7%	10.6%	-301.5%	5.5%	6.8%	4.9%
Dividend Yield	0.0%	0.0%	0.0%	0.0%	0.0%	2.2%	0.0%
FCF Yield 3Y Avg	8.9%	4.0%	1.9%	-1,449.2%	-6.3%	4.6%	3.0%
D/E	0.0	0.0	0.0	4.7	0.1	0.1	0.1
Net D/E	-0.1	-0.1	-0.2	3.5	0.0	0.0	-0.0

Returns

	ALKS	NBIX	ACAD	BTAI	INDV	JNJ	Median
Name	Alkermes	Neurocri.	ACADIA P.	BioXcel .	Indivior.	Johnson .
1M Rtn	20.6%	-0.6%	5.4%	-28.2%	-1.4%	-1.1%	-0.9%
3M Rtn	12.9%	-5.0%	-18.9%	-46.8%	-13.5%	17.4%	-9.3%
6M Rtn	7.3%	-5.6%	8.3%	-57.9%	28.9%	26.7%	7.8%
12M Rtn	24.0%	41.9%	49.0%	-40.9%	236.6%	61.7%	45.5%
3Y Rtn	20.5%	24.3%	17.3%	-99.7%	75.7%	57.2%	22.4%
1M Excs Rtn	20.0%	-1.1%	-1.7%	-32.5%	-7.2%	-2.3%	-2.0%
3M Excs Rtn	14.6%	-3.4%	-17.7%	-45.0%	-12.1%	18.2%	-7.8%
6M Excs Rtn	5.3%	-8.2%	1.0%	-60.7%	26.4%	26.4%	3.2%
12M Excs Rtn	-18.2%	10.5%	17.3%	-64.4%	199.6%	26.8%	13.9%
3Y Excs Rtn	-42.7%	-37.8%	-48.6%	-166.5%	11.7%	-1.6%	-40.3%

FDIC Bank Data

Bank Capital

null

Bank Deposits

null

Bank Assets

null

Bank Loans

null

FDA Approved Drugs Data

Expand for More

					Post-Approval Fwd Returns
FDA App #	Brand Name	Generic Name	Dosage Form	FDA Approval	3M Rtn	6M Rtn	1Y Rtn	2Y Rtn	Total Rtn
NDA213378	LYBALVI	olanzapine	tablet	5282021	37.2%	-0.9%	34.7%	29.3%	58.3%
NDA209830	ARISTADA INITIO KIT	aripiprazole lauroxil	suspension, extended release	6292018	3.1%	-30.8%	-45.2%	-54.3%	-12.8%
NDA207533	ARISTADA	aripiprazole lauroxil	suspension, extended release	10052015	25.2%	-39.2%	-22.8%	-13.2%	-40.0%
NDA021897	VIVITROL	naltrexone	for suspension, extended release	4132006	-24.0%	-26.7%	-29.6%	-49.4%	63.4%

	Post-Approval Fwd Returns
NDA213378	LYBALVI	olanzapine	tablet	5282021	37.2%	-0.9%	34.7%	29.3%	58.3%
NDA209830	ARISTADA INITIO KIT	aripiprazole lauroxil	suspension, extended release	6292018	3.1%	-30.8%	-45.2%	-54.3%	-12.8%
NDA207533	ARISTADA	aripiprazole lauroxil	suspension, extended release	10052015	25.2%	-39.2%	-22.8%	-13.2%	-40.0%
NDA021897	VIVITROL	naltrexone	for suspension, extended release	4132006	-24.0%	-26.7%	-29.6%	-49.4%	63.4%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2025	2024	2023	2022	2021	2020
Period End	12/31/2025	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020
Filing Date	2/25/2026	2/25/2026	2/12/2025	2/21/2024	2/16/2023	2/16/2022	2/11/2021
Key Financials
Total Revenue	1,476	1,476	1,558	1,663	1,112	1,174	1,039
EBITDA	331	331	495	519	60	178	-6
Operating Income	254	254	421	414	-6	98	-112
Net Income	242	242	367	356	-158	-48	-111
EPS	1.47	1.47	2.22	2.14	-0.97	-0.30	-0.70
Growth Rates
Total Revenue Growth	-5.2%	-5.2%	-6.4%	49.6%	-5.3%	13.0%	-11.3%
EBITDA Growth	-33.1%	-33.1%	-4.7%	769.1%	-66.3%	3048.2%	94.2%
Operating Income Growth	-39.6%	-39.6%	1.6%	6901.1%	-106.2%	186.9%	30.6%
Net Income Growth	-34.2%	-34.2%	3.2%	324.8%	-228.6%	56.6%	43.6%
Margins
EBITDA Margin	22.4%	22.4%	31.8%	31.2%	5.4%	15.1%	-0.6%
Operating Income Margin	17.2%	17.2%	27.0%	24.9%	-0.5%	8.3%	-10.8%
Net Income Margin	16.4%	16.4%	23.6%	21.4%	-14.2%	-4.1%	-10.7%
Cash & Debt
Total Cash	588	588	752	773	608	536	635
Total Debt	70	70	76	372	379	416	410
Net Debt / (Cash)	-518	-518	-676	-401	-229	-120	-225
Cash Flows
Net Cash from Operations	521	521	439	401	21	102	83
Free Cash from Operations	480	480	406	353	-17	73	41
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	-0	-0	200	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q4	2025Q3	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1
Period End	12/31/2025	9/30/2025	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023
Filing Date	2/25/2026	10/28/2025	7/29/2025	5/1/2025	2/12/2025	10/24/2024	7/24/2024	5/1/2024	2/21/2024	10/25/2023	7/26/2023	4/26/2023
Key Financials Quarterly
Total Revenue	385	394	391	307	430	378	399	350	377	381	617	288
Ebitda	76	109	113	33	181	123	129	61	83	117	307	13
Operating Income	58	89	93	14	163	105	110	43	55	89	281	-11
Net Income	49	83	87	22	147	92	91	37	113	48	237	-42
EPS	0.30	0.50	0.53	0.14	0.90	0.57	0.54	0.22	0.68	0.29	1.43	-0.25
Key Financials TTM
Total Revenue TTM	1,476	1,521	1,505	1,514	1,558	1,505	1,508	1,726	1,663	1,591	1,462	1,121
Ebitda TTM	331	436	450	467	495	396	391	568	519	576	414	96
Operating Income TTM	254	359	374	391	421	313	297	468	414	475	325	10
Net Income TTM	242	339	348	353	367	333	289	434	356	215	103	-164
Growth Rates Quarterly
Total Revenue Growth	-10.6%	4.2%	-2.1%	-12.5%	13.9%	-0.7%	-35.4%	21.8%	23.9%	51.0%	123.5%	3.2%
EBITDA Growth	-57.8%	-11.7%	-12.9%	-46.0%	118.8%	5.0%	-57.8%	381.1%	-40.3%	365.4%	2767.7%	154.0%
Operating Income Growth	-64.3%	-15.0%	-15.4%	-68.2%	197.8%	17.4%	-60.9%	494.7%	-52.7%	247.1%	916.3%	58.7%
Net Income Growth	-66.3%	-10.4%	-4.7%	-39.0%	29.9%	93.4%	-61.5%	188.0%	499.2%	174.7%	886.7%	-16.6%
Margins Quarterly
EBITDA Margin	19.9%	27.6%	28.8%	10.7%	42.2%	32.6%	32.4%	17.4%	22.0%	30.8%	49.6%	4.4%
Operating Income Margin	15.1%	22.6%	23.8%	4.5%	37.8%	27.7%	27.5%	12.4%	14.5%	23.4%	45.6%	-3.8%
Net Income Margin	12.8%	21.0%	22.3%	7.3%	34.1%	24.4%	22.9%	10.5%	29.9%	12.5%	38.4%	-14.5%
Cash & Debt
Total Cash	588	1,111	1,016	884	752	909	876	745	773	889	829	600
Total Debt	70	72	73	74	76	366	368	370	372	385	390	394
Net Debt / (Cash)	-518	-1,040	-943	-810	-676	-543	-508	-375	-401	-504	-440	-206
Cash Flows Quarterly
FCF from Operations	170	102	150	99	190	82	146	21	107	100	216	-21
Cash Flows TTM
FCF from Operations TTM	521	541	521	517	439	356	374	444	401	295	196	-22
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-0	-0	-0	-0	0	116	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	12.0%	28.5%	28.1%	4.0%	41.5%	24.3%	21.1%	7.3%	11.2%	16.6%	51.6%	-1.9%
Return on Invested Capital (ROIC) TTM
ROIC TTM	13.3%	29.4%	28.9%	27.3%	26.2%	21.5%	17.6%	23.8%	21.2%	21.4%	14.2%	0.4%

Segment Financials

Revenue by Segment

$ Mil	2025	2024	2023	2022	2021
Developing, manufacturing and commercializing medicines designed to address unmet medical needs of	1,558	1,663
License revenue			2	4	1
Manufacturing and royalty revenues			332	542	484
Product sales, net			778	627	552
Research and development revenue			0	1	2
Total	1,558	1,663	1,112	1,174	1,039

Net Income by Segment

$ Mil	2025	2024	2023	2022	2021
Developing, manufacturing and commercializing medicines designed to address unmet medical needs of	367	356
Total	367	356

Price Behavior

Price Behavior

Market Price	$33.36
Market Cap ($ Bil)	5.5
First Trading Date	07/16/1991
Distance from 52W High	-5.7%
	50 Days	200 Days
DMA Price	$31.46	$29.85
DMA Trend	indeterminate	indeterminate
Distance from DMA	6.1%	11.8%
	3M	1YR
Volatility	53.4%	40.0%
Downside Capture	-0.10	0.27
Upside Capture	58.17	64.17
Correlation (SPY)	16.7%	23.9%

ALKS Betas & Captures as of 3/31/2026

	1M	2M	3M	6M	1Y	3Y
Beta	0.53	0.72	0.72	0.68	0.65	0.57
Up Beta	-0.65	1.27	1.69	0.77	0.46	0.46
Down Beta	0.30	0.53	0.76	0.22	0.88	0.55
Up Capture	33%	5%	68%	92%	44%	31%
Bmk +ve Days	7	16	27	65	139	424
Stock +ve Days	12	17	32	59	125	370
Down Capture	21%	91%	21%	82%	86%	87%
Bmk -ve Days	12	23	33	58	110	323
Stock -ve Days	10	25	31	67	122	374

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Based On 1-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ALKS
ALKS	17.5%	40.6%	0.49	-
Sector ETF (XLV)	12.3%	16.8%	0.52	41.3%
Equity (SPY)	31.2%	17.3%	1.47	29.4%
Gold (GLD)	60.1%	27.8%	1.69	5.5%
Commodities (DBC)	29.8%	16.6%	1.58	3.2%
Real Estate (VNQ)	21.3%	15.2%	1.07	32.6%
Bitcoin (BTCUSD)	-4.3%	43.7%	0.02	17.2%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ALKS
ALKS	13.1%	37.0%	0.42	-
Sector ETF (XLV)	6.3%	14.6%	0.25	34.7%
Equity (SPY)	11.1%	17.0%	0.50	27.0%
Gold (GLD)	22.1%	17.8%	1.02	2.5%
Commodities (DBC)	11.8%	18.8%	0.52	2.6%
Real Estate (VNQ)	3.7%	18.8%	0.10	27.8%
Bitcoin (BTCUSD)	4.3%	56.5%	0.30	10.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 10-Year Data

	Annualized Return	Annualized Volatility	Sharpe Ratio	Correlation with ALKS
ALKS	-0.0%	41.4%	0.14	-
Sector ETF (XLV)	9.8%	16.5%	0.48	40.0%
Equity (SPY)	13.8%	17.9%	0.66	35.6%
Gold (GLD)	14.2%	15.9%	0.74	-0.3%
Commodities (DBC)	8.6%	17.6%	0.41	13.5%
Real Estate (VNQ)	5.1%	20.7%	0.22	27.3%
Bitcoin (BTCUSD)	67.6%	66.9%	1.07	8.1%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date	3312026
Short Interest: Shares Quantity	19.0 Mil
Short Interest: % Change Since 3152026	-7.7%
Average Daily Volume	3.2 Mil
Days-to-Cover Short Interest	5.9 days
Basic Shares Quantity	165.3 Mil
Short % of Basic Shares	11.5%

Returns Analyses

	Title
0	How Low Can Alkermes Stock Really Go?
1	Alkermes Stock Return Comparison
2	[10/15/2021] Alkermes (ALKS) Stock Price Forecast: AI Forecasts ALKS Stock Price To Be Around $31.80 In A Month (Up 0.3%)
3	Alkermes Total Shareholder Return (TSR): 12.3% in 2022 and 8.6% 3-yr returns (above peer average)
4	Alkermes (ALKS) Stock Return: AI Predicts ALKS Average and Excess Return After a Fall or Rise

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
1/12/2026	-0.1%	6.6%	17.1%
10/22/2025	-1.1%	-1.4%	-8.8%
7/29/2025	3.3%	1.9%	10.8%
5/1/2025	6.3%	5.6%	6.4%
1/13/2025	1.0%	5.0%	13.8%
10/24/2024	-3.6%	-5.5%	-0.5%
7/24/2024	6.0%	10.5%	13.0%
5/1/2024	-2.2%	0.2%	-5.4%
...
SUMMARY STATS
# Positive	11	12	13
# Negative	12	11	10
Median Positive	6.0%	5.3%	10.8%
Median Negative	-4.4%	-5.7%	-9.1%
Max Positive	16.3%	15.4%	27.0%
Max Negative	-12.7%	-14.3%	-27.4%

	Forward Returns
1/12/2026	-0.1%	6.6%	17.1%
10/22/2025	-1.1%	-1.4%	-8.8%
7/29/2025	3.3%	1.9%	10.8%
5/1/2025	6.3%	5.6%	6.4%
1/13/2025	1.0%	5.0%	13.8%
10/24/2024	-3.6%	-5.5%	-0.5%
7/24/2024	6.0%	10.5%	13.0%
5/1/2024	-2.2%	0.2%	-5.4%
2/15/2024	16.3%	3.3%	2.7%
10/25/2023	-7.4%	-4.5%	3.6%
7/26/2023	-2.6%	-7.5%	-9.5%
2/16/2023	4.4%	1.4%	-3.6%
11/2/2022	3.5%	-0.3%	8.4%
7/27/2022	-5.3%	-12.8%	-14.2%
4/27/2022	11.9%	6.9%	6.3%
2/16/2022	14.9%	3.5%	11.1%
10/27/2021	-9.1%	-5.7%	-27.4%
7/28/2021	6.8%	15.4%	27.0%
4/28/2021	-3.2%	-0.9%	-0.8%
2/11/2021	-12.7%	-14.3%	-15.3%
10/29/2020	5.8%	13.4%	20.2%
7/29/2020	-6.3%	-7.3%	-19.9%
4/29/2020	-10.6%	-11.1%	3.5%
SUMMARY STATS
# Positive	11	12	13
# Negative	12	11	10
Median Positive	6.0%	5.3%	10.8%
Median Negative	-4.4%	-5.7%	-9.1%
Max Positive	16.3%	15.4%	27.0%
Max Negative	-12.7%	-14.3%	-27.4%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
12/31/2025	02/25/2026	10-K
09/30/2025	10/28/2025	10-Q
06/30/2025	07/29/2025	10-Q
03/31/2025	05/01/2025	10-Q
12/31/2024	02/12/2025	10-K
09/30/2024	10/24/2024	10-Q
06/30/2024	07/24/2024	10-Q
03/31/2024	05/01/2024	10-Q
12/31/2023	02/21/2024	10-K
09/30/2023	10/25/2023	10-Q
06/30/2023	07/26/2023	10-Q
03/31/2023	04/26/2023	10-Q
12/31/2022	02/16/2023	10-K
09/30/2022	11/02/2022	10-Q
06/30/2022	07/27/2022	10-Q
03/31/2022	04/27/2022	10-Q

Recent Forward Guidance [BETA]

Latest: Q4 2025 Earnings Reported 2/25/2026

Forward Guidance				Guidance Change
Metric	Low	Mid	High	% Chg	% Delta	Change	Prior
2026 Total Revenues	1.73 Bil	1.78 Bil	1.84 Bil	22.3%		Higher New	Actual: 1.46 Bil for 2025
2026 VIVITROL Net Sales	460.00 Mil	470.00 Mil	480.00 Mil	1.1%		Higher New	Actual: 465.00 Mil for 2025
2026 LYBALVI Net Sales	380.00 Mil	390.00 Mil	400.00 Mil	13.0%		Higher New	Actual: 345.00 Mil for 2025
2026 ARISTADA Net Sales	365.00 Mil	375.00 Mil	385.00 Mil	2.7%		Higher New	Actual: 365.00 Mil for 2025
2026 R&D Expenses	445.00 Mil	465.00 Mil	485.00 Mil	45.3%		Higher New	Actual: 320.00 Mil for 2025
2026 SG&A Expenses	890.00 Mil	910.00 Mil	930.00 Mil	31.9%		Higher New	Actual: 690.00 Mil for 2025
2026 EBITDA	60.00 Mil	75.00 Mil	90.00 Mil	-73.2%		Lower New	Actual: 280.00 Mil for 2025
2026 Adjusted EBITDA	370.00 Mil	390.00 Mil	410.00 Mil	4.0%		Higher New	Actual: 375.00 Mil for 2025

Prior: Q3 2025 Earnings Reported 10/28/2025

null

Insider Activity

Expand for More

#	Owner	Title	Holding	Action	Filing Date	Price	Shares	Transacted Value	Value of Held Shares	Form
1	Hopkinson, Craig C	EVP R&D, Chief Medical Officer	Direct	Sell	1022026	28.00	4,000	112,000	1,728,720	Form
2	Hopkinson, Craig C	EVP R&D, Chief Medical Officer	Direct	Sell	12052025	30.00	3,748	112,447	1,972,325	Form
3	Hopkinson, Craig C	EVP R&D, Chief Medical Officer	Direct	Sell	12012025	29.30	4,000	117,200	1,926,182	Form
4	Hopkinson, Craig C	EVP R&D, Chief Medical Officer	Direct	Sell	11032025	30.38	9,000	273,442	2,118,869	Form
5	Hopkinson, Craig C	EVP R&D, Chief Medical Officer	Direct	Sell	10152025	31.53	9,000	283,776	2,325,074	Form

ALKS Trade Sentinel

Stock Conviction

null

CONVICTION RATIONALE

null

STOCK ARCHETYPE

null

INVESTMENT THESIS

null

Mechanism: null

Supporting Evidence:

PRIMARY RISK

null

Mechanism: null

Supporting Evidence:

Key KPI Watchlist

KPI	Threshold	Rationale

Core Investment Debate

BULL VIEW

CORE TENSION

PREVAILING SENTIMENT

BEAR VIEW

Next 6 months: Risks and Catalysts

Timeline	Event & Metric To Watch

Key Events in Last 6 Months

Date	Event	Stock Impact

Risk Management

Position Sizing

null

Diversification Alternatives

How Is The Market Pricing ALKS?

What will confirm the thesis

What will damage the thesis

Noise: Real but irrelevant to thesis

Repricing Catalyst

What ALKS Makes & Who Pays

TTM figures based on

ALKS Evolution: Price Return by Era

① Structure

② Volume / Momentum

③ Catalyst

Combined Score

0 / 12

1 Price Structure & Trend · ▾

2 Momentum ▾

3 Relative Strength vs. SPY ▾

4 Institutional Footprint & Volume ▾

5 Volatility ▾

6 Key Price Levels Range · Vol ▾

7 Earnings Reaction History ▾

8 How the Verdict Is Derived Three Pillars ▾

Pillar	Score
① Structure	0
② Vol / Mom	0
③ Catalyst	0

ℹ Bull Pillars: 0 · Bear Pillars: 0 · Combined Score: 0 →

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Alkermes (ALKS)

Market Price (4/12/2026): $33.48 | Market Cap: $5.5 BilSector: Health Care | Industry: Pharmaceuticals

Alkermes (ALKS)

Market Price (4/12/2026): $33.48Market Cap: $5.5 BilSector: Health CareIndustry: Pharmaceuticals

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Alkermes (ALKS)

Share Repurchases

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets vs. Alkermes (ALKS)

INDUSTRY: Pharmaceuticals

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

Higher Rev Chg LTM (Value for ALKS: -5.2%)

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

Higher Op Mgn LTM (Value for ALKS: 17.2%)

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

Higher Total Yield (Value for ALKS: 4.4%)

SECTOR: Health Care

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

Higher Rev Chg LTM (Value for ALKS: -5.2%)

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

Higher Op Mgn LTM (Value for ALKS: 17.2%)

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

Higher Total Yield (Value for ALKS: 4.4%)

All Other Sectors

Higher Rev Chg 3Y Avg | Lower P/S (Values for ALKS: 12.7% | 3.7x)

Higher Rev Chg 3Y Avg | Lower P/Op Inc (Values for ALKS: 12.7% | 21.7x)

Higher Rev Chg LTM (Value for ALKS: -5.2%)

Higher Rev Chg 3Y Avg (Value for ALKS: 12.7%)

Higher Op Mgn LTM (Value for ALKS: 17.2%)

Higher CFO/Rev LTM (Value for ALKS: 35.3%)

Higher FCF/Rev LTM (Value for ALKS: 32.5%)

Higher Total Yield (Value for ALKS: 4.4%)

Best Bets in Health Care

P/EBIT (Value for ALKS: 18.2x)

P/E (Value for ALKS: 22.8x)

Rev Chg 3Y Avg (Value for ALKS: 12.7%)

Rev Chg LTM (Value for ALKS: -5.2%)

Rev Chg Q (Value for ALKS: -10.6%)

FCF/Rev 3Y Avg (Value for ALKS: 26.6%)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

Top Gainers

Top Losers

Top Gainers

Top Losers

Top Gainers

Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons

Financials

Growth & Margins

Market Price (4/12/2026): $33.48 | Market Cap: $5.5 Bil
Sector: Health Care | Industry: Pharmaceuticals

Market Price (4/12/2026): $33.48
Market Cap: $5.5 Bil
Sector: Health Care
Industry: Pharmaceuticals